[1] 傅刘鹏,徐 俊,黄思超,等. 叶酸脂质体对乳腺癌4T1细胞的体内靶向性研究[J].山东医药, 2010,50(7):23-25.
[2] 高 芸,李少一,商雪莹,等. FAT10过表达对肝癌细胞HepG2侵袭及迁移能力的影响[J].实用预防医学, 2013,20(5):517-520.
[3] Giovanna D, Maurizio D. Contemporary pre-clinical development of anticancer agents-What are the optimal preclinical models?[J].Eur J Cancer,2009,45(16):2768-2781.
[4] Lu W, Xiong C, Zhang R, et al.Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors[J]. J Control Release,2012, 161(3): 959-966.
[5] Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities[J].J Control Release, 2010,141(3): 265-276.
[6] Yoo HS,Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles[J]. J Control Release, 2004,96(2): 273-283.
[7] Chung YI,Kima JC,Kim YH,et al.The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronie on tumor targeting[J].J Control Release,2010,143(3):374-382.
[8] Kirpotin DB,Drummond DC, Shao Y,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models[J].Cancer Res,2006,66(13): 6732-6740.
[9] Rooy I, Mastrobattista E, Storm G, et al. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain[J]. J Control Release, 2011,150(1): 30-36.
[10] Bareford LM, Swann PW. Endocytic mechanisms for targeted drug delivery[J]. Adv Drug Deliv Rev, 2007,59(8) :748-758.
[11] Paulos CM,Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery[J]. Mol Pharmacol, 2004,66(6): 1406-1414.
[12] Smet M, Heijman E, Langereis S,et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof of concept study[J].J Control Release, 2011,150(1): 102-110.
[13] Chen H, Kim S, He W, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging[J]. Langmuir, 2008,24(10): 5213-5217.
[14] Chen H, Kim S, Li L, et al. Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging[J]. Proc Natl Acad Sci USA, 2008,105(18): 6596-6601.
[15] Koo AN, Min KH, Lee HJ, et al.Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links[J]. Biomaterials, 2012,33(5): 1489-1499.
[16] Ishida T, Ichihara M, Wang X, et al. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes[J]. J Control Release, 2006,115(3): 243-250.
[17] Lu W,Wan J,She Z,et al.Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle[J].J Control Release,2007,118(1):38-53.
[18] Park K. To PEGylate or not to PEGylate, that is not the question[J]. J Control Release, 2010,142(2): 147-148.
[19] Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy[J]. Biochem Pharmacol, 2010,80(5): 762-770.
[20] Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells[J]. Cancer Res, 2006,66(2): 1033-1039.
[21] Netti PA, Berk DA, Swartz M A,et al. Role of etracellular matrix assembly in interstitial transport in solid tumors[J]. Cancer Res, 2000,60(9): 2497-2503.
[22] Brown E, Mckee TD, Tomaso ED, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation[J]. Nat Med, 2003,9(6): 796-800.
[23] Ramanujan S, Pluen A, Mckee TD, et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium[J]. Biophys J, 2002,83(3): 1650-1660.
[24] Alexandrakis G, Brown E, Tong RT, et al. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors[J]. Nat Med, 2004,10(2): 203-207.
[25] Ernsting MJ, Murakami M, Roy A, et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles[J]. J Control Release, 2013,172(3): 782-794.
[26] Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models[J]. Eur J Cancer, 2009,45(16): 2768-2781.